HC Wainwright & Co. Maintains Buy on Pliant Therapeutics, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Pliant Therapeutics (NASDAQ:PLRX) and raises the price target from $50 to $52.
September 27, 2023 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' price target has been raised from $50 to $52 by HC Wainwright & Co., maintaining a 'Buy' rating.
The news directly pertains to Pliant Therapeutics (PLRX). The raised price target and maintained 'Buy' rating by HC Wainwright & Co. is a positive signal for the company's stock, potentially leading to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100